HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunetherapeutics targeting infectious diseases based on its proprietary arenavirus platform. The company's immuno-oncology pipeline includes HB-700, a novel next-generation multi-KRAS mutant-targeting investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers; Eseba-vec, an investigational immunotherapeutic agent in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers with enrollment completed in a Phase 1/2 clinical trial; and HB-300, which targets self-antigens for the treatment of prostate cancer. It is also developing HB-400 for the treatment of Hepatitis B that is in Phase I of clinical trial; and HB-500 for the treatment of Human Immunodeficiency Virus (HIV) that is in Phase I of clinical trial. The company has a collaboration and license agreement with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products for the treatment, cure, diagnosis, or prevention of the hepatitis B virus (HBV) and the HIV. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.

Period	Debt/Equity
2019-12-31	0.15
2020-12-31	0.20
2021-12-31	0.41
2022-12-31	0.66
2023-12-31	0.80
2024-12-31	0.61

	A	B	C	D
1	Symbol	Price	Change	Volume
2	HOOK	$1.12	-1.75%	0.02M
3
4
5

HOOKIPA Pharma Inc. (HOOK) Debt to Equity Ratio

Debt to Equity Ratio Data

Get HOOKIPA Pharma Inc. Data in Excel

More HOOK Financial Data